Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer

Background: Palbociclib plus endocrine therapy (ET) demonstrated significant progression-free survival (PFS) benefit in Young Pearl, a randomized phase ll trial comparing palbociclib + ET versus capecitabine in premenopausal women with hormone receptor positive, HER2 negative metastatic breast cance...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Soohyeon Lee, Kyunghee Park, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Hee Kyung Ahn, Woong-Yang Park, Seock-Ah Im, Yeon Hee Park
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2022-04-01
Saila:	Breast
Gaiak:	Palbociclib Next-generation sequencing Progression-free survival Biomarker
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S0960977622000145
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!